Literature DB >> 15284307

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Geoffrey A Block1, Preston S Klassen, J Michael Lazarus, Norma Ofsthun, Edmund G Lowrie, Glenn M Chertow.   

Abstract

Mortality rates in ESRD are unacceptably high. Disorders of mineral metabolism (hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism) are potentially modifiable. For determining associations among disorders of mineral metabolism, mortality, and morbidity in hemodialysis patients, data on 40,538 hemodialysis patients with at least one determination of serum phosphorus and calcium during the last 3 mo of 1997 were analyzed. Unadjusted, case mix-adjusted, and multivariable-adjusted relative risks of death were calculated for categories of serum phosphorus, calcium, calcium x phosphorus product, and intact parathyroid hormone (PTH) using proportional hazards regression. Also determined was whether disorders of mineral metabolism were associated with all-cause, cardiovascular, infection-related, fracture-related, and vascular access-related hospitalization. After adjustment for case mix and laboratory variables, serum phosphorus concentrations >5.0 mg/dl were associated with an increased relative risk of death (1.07, 1.25, 1.43, 1.67, and 2.02 for serum phosphorus 5.0 to 6.0, 6.0 to 7.0, 7.0 to 8.0, 8.0 to 9.0, and >/=9.0 mg/dl). Higher adjusted serum calcium concentrations were also associated with an increased risk of death, even when examined within narrow ranges of serum phosphorus. Moderate to severe hyperparathyroidism (PTH concentrations >/=600 pg/ml) was associated with an increase in the relative risk of death, whereas more modest increases in PTH were not. When examined collectively, the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperphosphatemia. Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization. Disorders of mineral metabolism are independently associated with mortality and morbidity associated with cardiovascular disease and fracture in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284307     DOI: 10.1097/01.ASN.0000133041.27682.A2

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  705 in total

1.  Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.

Authors:  Manabu Okada; Yoshihiro Tominaga; Takahisa Hiramitsu; Toshihiro Ichimori
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

2.  Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Authors:  Cristina Karohl; Paolo Raggi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

3.  The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Authors:  Dan Li; Leping Shao; Haiyan Zhou; Wei Jiang; Wei Zhang; Yan Xu
Journal:  Endocrine       Date:  2012-06-06       Impact factor: 3.633

Review 4.  Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Chun-Juan Zhai; Xiao-Wei Yang; Jing Sun; Rong Wang
Journal:  Int Urol Nephrol       Date:  2014-11-16       Impact factor: 2.370

5.  Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey.

Authors:  Orlando M Gutiérrez; Tamara Isakova; Gwen Enfield; Myles Wolf
Journal:  J Ren Nutr       Date:  2010-05-26       Impact factor: 3.655

Review 6.  Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis.

Authors:  M Fusaro; A D'Angelo; G Scalzo; M Gallieni; S Giannini; G Guglielmi
Journal:  J Endocrinol Invest       Date:  2010-05       Impact factor: 4.256

7.  Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Authors:  Hirotaka Komaba; Mia Wang; Masatomo Taniguchi; Suguru Yamamoto; Takanobu Nomura; Douglas E Schaubel; Abigail R Smith; Jarcy Zee; Angelo Karaboyas; Brian Bieber; Masafumi Fukagawa; Francesca Tentori
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 8.237

8.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

9.  Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis.

Authors:  Cynthia Delgado; Stephanie Shieh; Barbara Grimes; Glenn M Chertow; Lorien S Dalrymple; George A Kaysen; John Kornak; Kirsten L Johansen
Journal:  Am J Nephrol       Date:  2015-09-19       Impact factor: 3.754

10.  A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Authors:  Björn Stollenwerk; Sergio Iannazzo; Ron Akehurst; Michael Adena; Andrew Briggs; Bastian Dehmel; Patrick Parfrey; Vasily Belozeroff
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.